# A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH

> **NCT06692283** · PHASE3 · WITHDRAWN · sponsor: **Sagimet Biosciences Inc.**

## Conditions studied

- MASLD
- MASH
- NASH
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Metabolic Dysfunction-Associated Steatohepatitis
- Nonalcoholic Steatohepatitis
- Nonalcoholic Fatty Liver

## Interventions

- **DRUG:** denifanstat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06692283
- **Lead sponsor:** Sagimet Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-03
- **Primary completion:** 2026-06
- **Final completion:** 2027-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06692283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06692283, "A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06692283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*